What If You Could Kill Cancer Before It Even Starts?

Why Smoldering Myeloma Is the Perfect Test Case

Think of smoldering myeloma like a pot of water on the stove. It's heating up, and you know it's going to boil. The question is when.

High-risk SMM patients face roughly a 50% chance of progressing to active myeloma within two years. By six years, as many as 80% to 90% will have crossed that threshold. Right now, the standard of care for these patients is frustratingly passive: watch and wait. Some clinical trials have tested early treatment with drugs like lenalidomide or daratumumab, and a meta-analysis in 2025 found that early therapy reduces progression risk by about 58%. One phase 3 trial even showed that daratumumab given for three years delayed progression and improved overall survival.

But CAR-T is a fundamentally different proposition. It's not a drug you take for years. It's a one-time infusion of living cells designed to seek and destroy a specific target. The logic behind CAR-PRISM is elegant: catch the disease when tumor burden is low, mutational complexity is minimal, and the immune system is still strong enough to support a robust CAR-T expansion.

Dana-Farber's investigators framed it this way: they wanted to treat patients "before they are exposed to therapies that can increase the chances of drug resistance, and before they transition into full-blown multiple myeloma." In other words, don't wait for the fire; put it out while it's still a spark.

The Interception Playbook

CAR-PRISM sits at the frontier of a broader movement in oncology called cancer interception: the idea of treating pre-malignant conditions before they become cancer, rather than waiting for a diagnosis and then fighting the disease. It's a concept with deep roots (removing colon polyps is a form of interception, after all) but has gained significant momentum in 2025 and 2026 as researchers identify immune biomarkers and molecular signatures in pre-cancerous tissue.

The appeal is obvious. Precursor lesions are simpler than full-blown tumors. They're less genetically diverse, less resistant, and theoretically easier to eradicate. A 2025 review described the approach as a "dual-window strategy": intervene early to normalize the microenvironment, then target the mutations driving progression.

CAR-T in smoldering myeloma is one of the first real-world tests of whether this philosophy can work with cellular therapy. And the early data suggest it can.

The Caveats (Because There Are Always Caveats)

Before anyone starts printing "Cancer Prevention Solved" t-shirts, let's pump the brakes.

CAR-PRISM enrolled 20 patients at a single center. That's not a typo. Twenty. There's no control arm, which means we can't directly compare these results to observation or to standard early interventions like lenalidomide. Fifteen months of follow-up is encouraging but hardly definitive; we need five-year and ten-year data to know whether these responses truly last.

There's also a philosophical tension. Some patients labeled "high risk" by older models may not actually progress for years, if ever. Newer analyses suggest that risk stratification tools aren't perfectly calibrated, raising concerns about overtreatment. Giving a complex, expensive cellular therapy to someone who might have been fine with monitoring is a genuine ethical question.

And then there's the practical stuff. CAR-T manufacturing is slow, costly, and occasionally fails. Even with improving logistics, scaling this to a prevention strategy for a broader population would be a massive undertaking.

Where This Goes Next

The pipeline tells you the industry is betting big on earlier-line CAR-T. Cilta-cel and ide-cel (the other approved BCMA CAR-T) are both being tested in patients with just one to three prior lines of therapy through trials like CARTITUDE-2 and KarMMa-2. A dual-target BCMA/CD19 CAR-T called GC012F hit 100% MRD-negativity at the deepest measurable level in 22 newly diagnosed high-risk myeloma patients. Next-generation platforms, including in vivo CAR-T that skips the manufacturing step entirely, could eventually make the whole process faster and cheaper.

If CAR-PRISM's results hold up in larger, multi-center trials with longer follow-up and a comparator arm, we could be looking at a genuine inflection point. Not just for myeloma, but for how we think about cancer altogether.

The question has always been: can we catch cancer early enough to stop it? For 20 patients at Dana-Farber, the answer, at least for now, is yes. The real test is whether that answer scales.

The 2-Year-Old Who Could Be Cured Before Kindergarten

The FDA just approved a CRISPR gene therapy for sickle cell patients as young as two years old, potentially offering a cure before the disease can cause lasting damage. But the $2.2 million price tag and chemo conditioning raise questions about who actually gets access.